These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18946055)

  • 1. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
    Watts GF; Chan DC
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1892-5. PubMed ID: 18946055
    [No Abstract]   [Full Text] [Related]  

  • 2. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice.
    Hernandez M; Wright SD; Cai TQ
    Biochem Biophys Res Commun; 2007 Apr; 355(4):1075-80. PubMed ID: 17335774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lp A-I and niacin: new views of an antiatherogenic duo.
    Saucan L; Brinton EA
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1707-9. PubMed ID: 11701453
    [No Abstract]   [Full Text] [Related]  

  • 5. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2008 Jul; 23(4):426-9. PubMed ID: 18536113
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reverse cholesterol transport processes and their role in artherosclerosis regression].
    Chachaj A; Drozdz K; Szuba A
    Postepy Biochem; 2008; 54(3):301-7. PubMed ID: 19112829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of CLA-1 and human PDZK1 in murine liver modulates HDL cholesterol metabolism.
    Komori H; Arai H; Kashima T; Huby T; Kita T; Ueda Y
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1298-303. PubMed ID: 18403724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.
    Salerno AG; Patrício PR; Berti JA; Oliveira HC
    Biochem J; 2009 May; 419(3):629-34. PubMed ID: 19191759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: review and hypothesis.
    Dergunov AD; Visvikis-Siest S; Siest G
    Vascul Pharmacol; 2008; 48(2-3):70-5. PubMed ID: 18221919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
    Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
    Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
    Kühnast S; Louwe MC; Heemskerk MM; Pieterman EJ; van Klinken JB; van den Berg SA; Smit JW; Havekes LM; Rensen PC; van der Hoorn JW; Princen HM; Jukema JW
    PLoS One; 2013; 8(6):e66467. PubMed ID: 23840481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.
    Li Z; Wang Y; van der Sluis RJ; van der Hoorn JW; Princen HM; Van Eck M; Van Berkel TJ; Rensen PC; Hoekstra M
    Biochem Pharmacol; 2012 Sep; 84(6):821-9. PubMed ID: 22750059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.
    Schmidt D; Smenton A; Raghavan S; Carballo-Jane E; Lubell S; Ciecko T; Holt TG; Wolff M; Taggart A; Wilsie L; Krsmanovic M; Ren N; Blom D; Cheng K; McCann PE; Gerard Waters M; Tata J; Colletti S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4768-72. PubMed ID: 19592242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 15. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema.
    Birjmohun RS; Kees Hovingh G; Stroes ES; Hofstra JJ; Dallinga-Thie GM; Meijers JC; Kastelein JJ; Levi M
    Clin Ther; 2008 Dec; 30(12):2314-23. PubMed ID: 19167590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoM: gene regulation and effects on HDL metabolism.
    Nielsen LB; Christoffersen C; Ahnström J; Dahlbäck B
    Trends Endocrinol Metab; 2009 Mar; 20(2):66-71. PubMed ID: 19200746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
    Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
    Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.